SelectImmune Pharma files important patent application for acute pyelonephritis

Report this content

SelectImmune Pharma AB has filed for patent protection over a range of new agents that show surprising levels of activity in treatment of pyelonephritis. This new patent application adds to SelectImmune Pharma’s expanding range of intellectual property rights in the pharmaceutical sector, specifically for treating bacterial infections.

Acute pyelonephritis or kidney infection, is a severe and common form of urinary tract infection, caused by bacteria that directly infect the kidneys. In about 30% of adults with acute pyelonephritis, bacteria invade the blood stream, causing urosepsis and without appropriate treatment, mortality is high. Acute pyelonephritis is also common in childhood, and may cause long-term problems by damaging renal tissue.

Following extensive research at Lund University into new treatment options for acute pyelonephritis, efficient new approaches have now been identified and the therapeutic effects confirmed in animal models, strengthening the commitment to develop these substances for future clinical use.

We are delighted to make progress for this important patient group, through our molecular studies of disease determinants and the response to infection,” says Catharina Svanborg, Chaiman of the board, SelectImmune Pharma.

"Selectimmune Pharma is pleased to announce a continued strengthening of its intellectual property portfolio through this new patent application for treatment of pyelonephritis,’’ says Ann Gidner, CEO of SelectImmune Pharma.

For more information, please contact:

Catharina Svanborg

Chairman of the board SelectImmune Pharma AB

Phone: +46 709 42 65 49


Ann Gidner

CEO SelectImmune Pharma AB

Phone: +46 768 17 14 14


This disclosure contains information that SelectImmune is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 01-02-2022 10:37 CET.

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.

Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can supplement or replace antibiotics. Urinary tract infections (UVI) are one of the world’s most common infectious diseases, affecting about 150 million people each year. The need for alternative treatments for bacterial infections is currently very large as are potential markets.


Documents & Links